References
- Abdulrahman R.M., Verloop H., Hoftijzer H., Verburg E., Hovens G.C., Corssmit E.P., Reiners C., Gelderblom H., Pereira A.M., Kapiteijn E., Romijn J.A., Visser T.J., Smit J.W.: Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J. Clin. Endocrinol. Metab., 2010; 95: 3758–3762
- Angell T.E.: Thyroiditis while receiving programmed death ligand 1 (PD-L1) inhibitor therapy for nonthyroid cancers is associated with improved overall survival. Clin. Thyroidol., 2020; 32: 65–68
- Arima H., Iwama S., Inaba H., Ariyasu H., Makita N., Otsuki M., Kageyama K., Imagawa A., Akamizu T.: Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocr. J., 2019; 66: 581–586
- Baldazzi V., Tassi R., Lapini A., Lunghi A., Garofoli E., Caruso S., Carini M., Mazzanti R.: Sunitinib-induced hyperparathyroidism: A possible mechanism to altered bone homeostasis. Cancer, 2012; 118: 3165–3172
- Barroso-Sousa R., Barry W.T., Garrido-Castro A.C., Hodi F.S., Min L., Krop I.E., Tolaney S.M.: Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA Oncol., 2018; 4: 173–182
- Bjornsti M.A., Houghton P.J: The TOR pathway: A target for cancer therapy. Nat. Rev. Cancer, 2004; 4: 335–348
- Blagosklonny M.V.: Fasting and rapamycin: Diabetes versus benevolent glucose intolerance. Cell Death Dis., 2019; 10: 607
- Blagosklonny M.V.: Rapamycin for longevity: Opinion article. Aging, 2019; 11: 8048–8067
- Brancatella A., Viola N., Brogioni S., Montanelli L., Sardella C., Vitti P., Marcocci C., Lupi I., Latrofa F.: Graves’ disease induced by immune checkpoint inhibitors: A case report and review of the literature. Eur. Thyroid J., 2019; 8: 192–195
- Braun D., Kim T.D., le Coutre P., Köhrle J., Hershman J.M., Schweizer U.: Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J. Clin. Endocrinol. Metab., 2012; 97: E100–E105
- Buffier P., Bouillet B., Smati S., Archambeaud F., Cariou B., Verges B.: Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors. Ann. Endocrinol., 2018; 79: 574–582
- Castinetti F., Albarel F., Archambeaud F., Bertherat J., Bouillet B., Buffier P., Briet C., Cariou B., Caron P., Chabre O., Chanson P., Cortet C., Do Cao C., Drui D., Haissaguerre M. i wsp.: Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions. Ann. Endocrinol., 2018; 79: 591–595
- Castinetti F., Borson-Chazot F.: Introduction to expert opinion on endocrine complications of new anticancer therapies. Ann. Endocrinol., 2018; 79: 535–538
- Clemons J., Gao D., Naam M., Breaker K., Garfield D., Flaig T.W.: Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin. Genitourin. Cancer, 2012; 10: 225–231
- Corsello S.M., Barnabei A., Marchetti P., De Vecchis L., Salvatori R., Torino F.: Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab., 2013; 98: 1361–1375
- Darvin P., Toor S.M., Nair V.S, Elkord E.: Immune checkpoint inhibitors: Recent progress and potential biomarkers. Exp. Mol. Med., 2018; 50: 1–11
- de Filette J., Andreescu C.E., Cools F., Bravenboer B., Velkeniers B.: A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm. Metab. Res., 2019; 51: 145–156
- de Filette J.M., Pen J.J., Decoster L., Vissers T., Bravenboer B., Van der Auwera B.J., Gorus F.K., Roep B.O., Aspeslagh S., Neyns B., Velkeniers B., Kharagjitsingh A.V.: Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review. Eur. J. Endocrinol., 2019; 181: 363–374
- Deligiorgi M.V., Panayiotidis M.I., Trafalis D.T.: Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions. Int. Immunopharmacol., 2019; 77: 105942
- Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B. i wsp.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med., 2002; 347: 472–480
- Feldt S., Schüssel K., Quinzler R., Franzmann A., Czeche S., Ludwig W.D., Schulz M.: Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: A cohort study. Eur. J. Cancer, 2012; 48: 974–981
- Fountas A., Diamantopoulos L.N., Tsatsoulis A.: Tyrosine kinase inhibitors and diabetes: A novel treatment paradigm? Trends Endocrinol. Metab., 2015; 26: 643–656
- Fraenkel M., Ketzinel-Gilad M., Ariav Y., Pappo O., Karaca M., Castel J., Berthault M.F., Magnan C., Cerasi E., Kaiser N., Leibowitz G.: mTOR inhibition by rapamycin prevents – β cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes, 2008; 57: 945–957
- Green M.R., Newton M.D., Fancher K.M.: Off-target effects of BCR-ABL and JAK2 inhibitors. Am. J. Clin. Oncol., 2016; 39: 76–84
- Guertin D.A, Sabatini D.M.: Defining the role of mTOR in cancer. Cancer Cell, 2007; 12: 9–22
- Gutierrez C., McEvoy C., Munshi L., Stephens R.S., Detsky M.E., Nates J.L., Pastores S.M.: Critical care management of toxicities associated with targeted agents and immunotherapies for cancer. Crit. Care Med., 2020; 48: 10–21
- Hay N., Sonenberg N.: Upstream and downstream of mTOR. Genes Dev., 2004; 18: 1926–1945
- Iyer P.C, Cabanillas M.E., Waguespack S.G., Hu M.I., Thosani S., Lavis V.R., Busaidy N.L., Subudhi S.K., Diab A., Dadu R.: Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid, 2018; 28: 1243–1251
- Kappers M.H.W., van Esch J.H.M., Smedts F.M.M., de Krijger R.R., Eechoute K., Mathijssen R.H.J., Sleijfer S., Leijten F., Danser A.H.J., van den Meiracker A.H., Visser T.J.: Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J. Clin. Endocrinol. Metab., 2011; 96: 3087–3094
- Kassi E., Angelousi A., Asonitis N., Diamantopoulos P., Anastasopoulou A., Papaxoinis G., Kokkinos M., Giovanopoulos I., Kyriakakis G., Petychaki F., Savelli A., Benopoulou O., Gogas H.: Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. Cancer Med., 2019; 8: 6585–6594
- Kitajima K., Takahashi S., Maeda T., Yoshikawa T., Ohno Y., Fujii M., Miyake H., Fujisawa M., Sugimura K.: Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: Comparison with thyroid function. Eur. J. Radiol., 2012; 81: 2060–2065
- Kluczyński Ł., Gilis-Januszewska A., Rogoziński D., Pantofliński J., Hubalewska-Dydejczyk A.: Hypophysitis-new insights into diagnosis and treatment. Endokrynol. Pol., 2019; 70: 260–269
- Kobayashi T., Iwama S., Yasuda Y., Okada N., Tsunekawa T., Onoue T., Takagi H., Hagiwara D., Ito Y., Morishita Y., Goto M., Suga H., Banno R., Yokota K. i wsp.: Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: A prospective study. J. Endocr. Soc., 2018; 2: 241–251
- Kotwal A., Haddox C., Block M., Kudva Y.C.: Immune checkpoint inhibitors: An emerging cause of insulin-dependent diabetes. BMJ Open Diab. Res. Care, 2019; 7: e000591
- Kraig E., Linehan L.A., Liang H., Romo T.Q., Liu Q., Wu Y., Benavides A.D., Curiel T.J., Javors M.A., Musi N., Chiodo L., Koek W., Gelfond J.A.L., Kellogg D.L.Jr.: A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Exp. Gerontol., 2018; 105: 53–69
- Krajewska J., Paliczka-Cieslik E., Jarzab B.: Managing tyrosine kinase inhibitors side effects in thyroid cancer. Expert Rev. Endocrinol. Metab., 2017; 12: 117–127
- Król A., Gawlik T., Jarząb B.: Endocrine complications of cancer immunotherapy. Endokrynol. Pol., 2018; 69: 722–733
- Kroschinsky F., Stölzel F., von Bonin S., Beutel G., Kochanek M., Kiehl M., Schellongowski P., Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group: New drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management. Crit. Care, 2017; 21: 89
- Kyi C., Postow M.A.: Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett., 2014; 588: 368–376
- Lanzolla G., Coppelli A., Cosottini M., Del Prato S., Marcocci C., Lupi I.: Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome. J. Endocr. Soc., 2019; 3: 496–503
- Li J., Wang M., Zhang B., Wu X., Lin T.L., Liu X.F., Zhou Y., Zhang X.H., Xu H., Shen L.J., Zou J., Lu P., Zhang D., Gu W.J., Zhang M.X., Pan J., Cao H., Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association: Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors. World J. Gastroenterol., 2018; 24: 5189–5202
- Liu S., Kurzrock R.: Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treat. Rev., 2014; 40: 883–891
- Lu J., Li L., Lan Y., Liang Y., Meng H.: Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis. Cancer Med., 2019; 8: 7503–7515
- Lupu J., Pages C., Laly P., Delyon J., Laloi M., Petit A., Basset-Seguin N., Oueslati I., Zagdanski A.M., Young J., Bouche C., Lebbé C., Gautier J.F.: Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination. Melanoma Res., 2017; 27: 649–652
- Makita N., Iiri T.: Tyrosine kinase inhibitor-induced thyroid disorders: A review and hypothesis. Thyroid, 2013; 23: 151–159
- Makita N., Miyakawa M., Fujita T., Iiri T.: Sunitinib induces hypothyroidism with a markedly reduced vascularity. Thyroid, 2010; 20: 323–326
- Mannavola D., Coco P., Vannucchi G., Bertuelli R., Carletto M., Casali P.G., Beck-Peccoz P., Fugazzola L.: A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J. Clin. Endocrinol. Metab., 2007; 92: 3531–3534
- Marcq E., Waele J.D., Audenaerde J.V., Lion E., Santermans E., Hens N., Pauwels P., van Meerbeeck J.P., Smits E.L.J.: Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients. Oncotarget, 2017; 8: 89722–89735
- Martins F., de Oliveira M.A., Wang Q., Sonis S., Gallottini M., George S., Treister N.: A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol., 2013; 49: 293–298
- Matrana M.R., Duran C., Shetty A., Xiao L., Atkinson B.J., Corn P., Pagliaro L.C., Millikan R.E., Charnsangave C., Jonasch E., Tannir N.M.: Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur. J. Cancer, 2013; 49: 3169–3175
- Min L., Vaidya A., Becker C.: Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur. J. Endocrinol., 2011; 164: 303–307
- Neumann D., Korzeniowska K., Jankowski J., Jabłecka A.: Kardiotoksyczność leczenia przeciwnowotworowego. Chor. Serca Naczyń, 2016; 13: 434–444
- Nurgali K., Jagoe R.T., Abalo R.: Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front Pharmacol., 2018; 9: 245
- Ohba K., Takayama T., Matsunaga H., Matsushita A., Sasaki S., Oki Y., Ozono S., Nakamura H.: Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib. Thyroid, 2013; 23: 443–448
- Pal S.K., Miller M.J., Agarwal N., Chang S.M., Chavez-MacGregor M., Cohen E., Cole S., Dale W., Magid Diefenbach C.S., Disis M.L., Dreicer R., Graham D.L., Henry N.L., Jones J., Keedy V. i wsp.: Clinical cancer advances 2019: Annual report on progress against cancer from the American Society of Clinical Oncology. J. Clin. Oncol., 2019; 37: 834–849
- Paul M.K., Mukhopadhyay A.K.: Tyrosine kinase – Role and significance in cancer. Int. J. Med. Sci., 2004; 1: 101–115
- Piranavan P., Li Y., Brown E., Kemp E.H., Trivedi N.: Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies. J. Clin. Endocrinol. Metab., 2019; 104: 550–556
- Płużański A., Piórek A.: Side effects of tyrosine kinase inhibitors — management guidelines. Oncol. Clin. Pract., 2016; 12: 113–118
- Prete A., Salvatori R.: Hypophysitis. https://www.ncbi.nlm.nih.gov/books/NBK519842 (15.08.2018)
- Rini B.I., Tamaskar I., Shaheen P., Salas R., Garcia J., Wood L., Reddy S., Dreicer R., Bukowski R.M.: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Nat. Cancer Inst., 2007; 99: 81–83
- Sagiv O., Kandl T.J, Thakar S.D., Thuro B.A, Busaidy N.L., Cabanillas M., Jimenez C., Dadu R., Graham P.H., Debnam J.M., Esmaeli B.: Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthalmic Plast. Reconstr. Surg., 2019; 35: 50–52
- Santoni M., Conti A., Massari F., Di Nunno V., Faloppi L., Galizia E., Morbiducci J., Piva F., Buti S., Iacovelli R., Ferretti B., Cimadamore A., Scarpelli M., Lopez-Beltran A., Cheng L., Battelli N., Montironi R.: Targeted therapy for solid tumors and risk of hypertension: A meta-analysis of 68077 patients from 93 phase III studies. Exp. Rev. Cardiovasc. Ther., 2019; 17: 917–927
- Shu M., Zai X., Zhang B., Wang R., Lin Z.: Hypothyroidism side effect in patients treated with sunitinib or sorafenib: Clinical and structural analyses. PLoS One, 2016; 11: e0147048
- Sivendran S., Agarwal N., Gartrell B., Ying J., Boucher K.M., Choueiri T.K., Sonpavde G., Oh W.K., Galsky M.D.: Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat. Rev., 2014; 40: 190–196
- Sobańska K., Szałek E., Kamińska A., Grześkowiak E.: Inhibitory kinaz tyrozynowych w terapii przeciwnowotworowej. Farm. Współ., 2011; 4: 185–190
- Sosa A., Lopez Cadena E., Simon Olive C., Karachaliou N., Rosell R.: Clinical assessment of immune-related adverse events. Ther. Adv. Med. Oncol., 2018; 10: 1758835918764628
- Tamaskar I., Bukowski R., Elson P., Ioachimescu A.G., Wood L., Dreicer R., Mekhail T., Garcia J., Rini B.I.: Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann. Oncol., 2008; 19: 265–268
- Tan M.H., Iyengar R., Mizokami-Stout K., Yentz S., MacEachern M.P., Shen L.Y., Redman B., Gianchandani R.: Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: A scoping review of case reports. Clin. Diabet. Endocrinol., 2019; 5: 1
- Torino F., Barnabei A., Paragliola R.M., Marchetti P., Salvatori R., Corsello S.M.: Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur. J. Endocrinol., 2013; 169: R153–R164
- Verloop H., Smit J.W., Dekkers O.M.: Sorafenib therapy decreases the clearance of thyrotropin. Eur. J. Endocrinol., 2013; 168: 163–167
- Veroux M., Tallarita T., Corona D., Sinagra N., Giaquinta A., Zerbo D., Guerrieri C., D’Assoro A., Cimino S., Veroux P.: Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation. Clin. Dev. Immunol., 2013; 2013: 496974
- Walko C.M., Aubert R.E., La-Beck N.M., Clore G., Herrera V., Kourlas H., Epstein R.S., McLeod H.L.: Pharmacoepidemiology of clinically relevant hypothyroidism and hypertension from sunitinib and sorafenib. Oncologist, 2017; 22: 208–212
- Wang D.Y., Salem J.E., Cohen J.V., Chandra S., Menzer C., Ye F., Zhao S., Das S., Beckermann K.E., Ha L., Rathmell W.K., Ancell K.K., Balko J.M., Bowman C., Davis E.J. i wsp.: Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol., 2018; 4: 1721–1728
- Wong E., Rosen L.S., Mulay M., Vanvugt A., Dinolfo M., Tomoda C., Sugawara M., Hershman J.M.: Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid, 2007; 17: 351–355
- Yajima K., Akise Y.: A case report of Graves’ disease induced by the anti-human programmed cell death-1 monoclonal antibody pembrolizumab in a bladder cancer patient. Case Rep. Endocrinol., 2019; 2019: 2314032
- Yang J.C., Reguart N., Barinoff J., Köhler J., Uttenreuther-Fischer M., Stammberger U., O’Brien D., Wolf J., Cohen E.E.: Diarrhea associated with afatinib: An oral ErbB family blocker. Expert Rev. Anticancer Ther., 2013; 13: 729–736
- Zhao C., Tella S.H., Del Rivero J., Kommalapati A., Ebenuwa I., Gulley J., Strauss J., Brownell I.: Anti-PD-L1 treatment induced central diabetes insipidus. J. Clin. Endocrinol. Metab., 2018; 103: 365–369